Technical Updates, Product Approvals, and Project Sanctions - Research Reports on Occidental, Dow Chemical, Hess, BP and Cabot

NEW YORK, August 21, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Occidental Petroleum Corporation (NYSE: OXY), The Dow Chemical Company (NYSE: DOW), Hess Corp. (NYSE: HES), BP Plc (NYSE: BP) and Cabot Oil & Gas Corporation (NYSE: COG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5875-100free.

Occidental Petroleum Corporation Research Reports

On August 18, 2014, Occidental Petroleum Corporation's (Occidental) stock ended the day 0.14% higher at $100.60, following the Dow Jones Industrial Average that moved up 1.06% over the same trading session. Shares in Occidental opened at $100.78 and oscillated within the range of $99.49 - $100.90. The stock is trading near its 52-week high of $105.64. Over the past three months, the stock has returned 4.86%, outperforming the Dow Jones Industrial Average that returned 1.98% over the same period of time. The full research reports on Occidental are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/OXY/report.pdf

The Dow Chemical Company Research Reports

On August 13, 2014, The Dow Chemical Company (Dow Chemical) reported that its business unit, Dow Microbial Control, has received the European Union regulatory approval for its antifouling active substance DCOIT (4,5-Dichloro-2-octyl-2H-isothiazol-3-one), an innovative technology used in paints and coatings to prevent the settlement of unwanted organisms on the surface of structures immersed in water. Dow Chemical informed that antifouling products are used to control the unwanted growth and settlement of fouling organisms on marine vessels, aquaculture equipment or other structures used in water. Further, the European Commission has approved DCOIT for use in coating formulations that are included in the Biocidal Products Regulation (BPR) "Product Type 21," which covers antifouling products. Mark Henning, Global Business Director for Dow Microbial Control, said, "This landmark EU approval confirms an excellent environmental profile for DCOIT as an antifouling agent for commercial fleets, superyachts, nets and other marine structures." The full research reports on Dow Chemical are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/DOW/report.pdf

Hess Corp. Research Reports

On August 18, 2014, shares in Hess Corp. (Hess) ended the day 1.01% lower at $97.90. Hess' stock opened the session at $99.21 and fluctuated between $96.93 and $99.44. The stock has a 52-week high of $104.50 and a 52-week low of $72.62. Over the past three months, the stock has gained 11.33%, outperforming the S&P 500 that gained 4.60% over the same time period. The full research reports on Hess are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/HES/report.pdf

BP Plc Research Reports

On August 13, 2014, BP Plc (BP) reported that its subsidiary, BP Trinidad and Tobago LLC, announced the sanction of its Juniper offshore gas project, which will feature the construction of a normally unmanned platform along with corresponding subsea infrastructure, with fabrication proposed to begin in Q4 2014. The Juniper facility will procure gas from the Corallita and Lantana fields located 50 miles off the south east coast of Trinidad in water-depth of approximately 360 feet. Further, the developments will include five subsea wells with a production capacity of approximately 590 million standard cubic feet a day (mmscfd). Drilling is expected to begin in 2015, and first gas from the facility is expected in 2017. The full research reports on BP are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/BP/report.pdf

Cabot Oil & Gas Corporation Research Reports

On August 18, 2014, shares in Cabot Oil & Gas Corporation (Cabot) moved up 0.51% to end the trading session at $33.19, tracking gains in the broader market. The stock opened at $33.15 and fluctuated between $32.70 and $33.35. The stock has a 52-week high of $41.78 and a 52-week low of $31.79. The full research reports on Cabot are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/COG/report.pdf

About Analysts Review

We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review